We examined the basis for the absence in cystic fibrosis (CF) patients of opsonic antibodies to the mucoid exopolysaccharide (MEP) antigen surrounding Pseudomonas aeruginosa that infect these patients. Opsonic antibodies to MEP are found in sera of the minority of CF patients that remain noncolonized into the second to fourth decades of life and protect rodents from chronic P. aeruginosa endobronchial infections. High titers of nonopsonic antibodies to MEP are found in P. aeruginosa-infected CF patients. Immunization of mice with doses of MEP that provoke only nonopsonic antibodies elicited CD3+, CD8+, T cell receptor alpha beta receptor+, major histocompatibility complex-unrestricted cytotoxic lymphocytes specific for hybridoma cells producing opsonic but not nonopsonic antibodies. Cytotoxicity was dependent on immune complexes on the surface of the T cells. Normal murine T cells could be activated by concanavalin A and sensitized with immune complexes for cytotoxic killing of hybridoma targets. CF patients infected with P. aeruginosa had serum immune complexes that sensitized concanavalin A-activated human T cells to kill murine hybridoma cells producing opsonic but not nonopsonic antibody. These results could explain the absence in infected CF patients of MEP-specific opsonins, an occurrence that accompanies the persistence of this infectious state.
G B Pier, S Takeda, M Grout, R B Markham
Title and authors | Publication | Year |
---|---|---|
Vaccines for Pseudomonas aeruginosa : a long and winding road
GP Priebe, JB Goldberg |
Expert Review of Vaccines | 2014 |
Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa
RR Lovewell, YR Patankar, B Berwin |
American journal of physiology. Lung cellular and molecular physiology | 2014 |
Targeting Pan-Resistant Bacteria With Antibodies to a Broadly Conserved Surface Polysaccharide Expressed During Infection
D Skurnik, MR Davis, D Benedetti, KL Moravec, C Cywes-Bentley, D Roux, DC Traficante, RL Walsh, T Maira-Litran, SK Cassidy, CR Hermos, TR Martin, EL Thakkallapalli, SO Vargas, AJ McAdam, TD Lieberman, R Kishony, JJ LiPuma, GB Pier, JB Goldberg, GP Priebe |
The Journal of Infectious Diseases | 2012 |
Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis
AR Hauser, M Jain, M Bar-Meir, SA McColley |
Clinical microbiology reviews | 2011 |
State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?
JF Chmiel, PB Davis |
Respiratory Research | 2003 |
New Bacterial Vaccines
RW Ellis, BR Brodeur |
2003 | |
Medical Implications of Biofilms
M Wilson, D Devine |
2003 | |
Rheumatic disease and cystic fibrosis
PA Merkel |
Arthritis & Rheumatism | 1999 |
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia
JR Govan, V Deretic |
Microbiological reviews | 1996 |
Pseudomonas aeruginosa exoenzyme S induces proliferation of human T lymphocytes
CH Mody, DE Buser, RM Syme, DE Woods |
Infection and immunity | 1995 |
Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine
GB Pier, D DesJardin, M Grout, C Garner, SE Bennett, G Pekoe, SA Fuller, MO Thornton, WS Harkonen, HC Miller |
Infection and immunity | 1994 |